Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sonicare BreathRx Tongue Spray** is an alcohol-free topical oral OTC antimicrobial spray developed for management of halitosis. Its drug active ingredient is cetylpyridinium chloride, a quaternary ammonium antiseptic that disrupts bacterial cell membranes and reduces odor-causing oral bacteria. The formulation also incorporates Zytex, a proprietary zinc, thymol, and eucalyptus-oil blend intended to neutralize volatile sulfur compounds responsible for oral malodour. It was designed for application to the tongue, including use with the Philips Sonicare TongueCare+ tongue brush; Philips lists the product as discontinued. ([usa.philips.com](https://www.usa.philips.com/c-p/DIS640_03/sonicare-breathrx-tongue-spray))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sonicare BreathRx Tongue Spray.